The long-acting interleukin-7 NT-I7 is safe and increases absolute lymphocyte counts and CD4 T-cell counts in patients with newly diagnosed high-grade gliomas with severe treatment-related CD4 lymphopenia. This evidence concerns the gene CD4 and lymphopenia.